Masy Pharma SRL
Masy Pharma reported total assets of 700,251 € at the end of the 2025 financial year (annual accounts filed with the NBB on 20 Aug 2026).
The score of Masy Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +6 % Total assets -17 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Masy Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 5,768 € | ||||
| Equity | 475,544 € | ||||
| Cash | 63,849 € | ||||
| EBITDA | 14,928 € | ||||
| Total assets | 700,251 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 20 Aug 2026
- Year ended 31 Dec 2024filed on 19 Aug 2025
- Year ended 31 Dec 2023filed on 25 Jun 2024
- Year ended 31 Dec 2022filed on 27 Jun 2023
- Year ended 31 Dec 2021filed on 15 Jul 2022
Masy Pharma's financial analysis
- Solvency67.9%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Masy Pharma
Masy Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0429.997.139
- VAT number
- BE0429997139
- Peppol
- Registered · 0208:0429997139 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 17 Dec 1986
- Registered office
- 1800 Vilvoorde
- Latest accounts
- 2025 · filed on 20 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Masy Pharma (SRL) has been based in Vilvoorde since 1986, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 5,768 € and equity of 475,544 €; its revenue is not published. Its solvency stands at 67.9%, above the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Masy Pharma
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Curavit Retail sale of pharmaceutical products Kalmthout · balance sheet 700,757 €
- Houmanfarma Retail sale of pharmaceutical products Meise · balance sheet 700,955 €
- Pharmacie Lecompt Retail sale of pharmaceutical products Quaregnon · balance sheet 701,179 €
- Mepharma Retail sale of pharmaceutical products Merelbeke-Melle · balance sheet 701,340 €
- West Pharma Retail sale of pharmaceutical products Anderlecht · balance sheet 701,649 €
- Apopharma Retail sale of pharmaceutical products Wezembeek-Oppem · balance sheet 702,319 €
- MT Pharma Retail sale of pharmaceutical products Léglise · balance sheet 697,338 €
- AKBM Retail sale of pharmaceutical products Izegem · balance sheet 697,186 €
Frequently asked questions about Masy Pharma
What is the revenue of Masy Pharma?
Masy Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Masy Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0429997139 for Masy Pharma, if the company is VAT-registered. Its company number (CBE) is 0429.997.139.
Where is the registered office of Masy Pharma?
According to the CBE register, the registered office of Masy Pharma is in 1800 Vilvoorde.
What is the equity of Masy Pharma?
At the close of the 2025 financial year, the equity of Masy Pharma amounts to 475,544 €, a solvency of 67.9% of total assets.
Who manages Masy Pharma?
The register lists 2 active mandates at Masy Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Masy Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →